标签： 花旗将Hims & Hers Health的目标价从16.5美元下调至13.25美元，维持"卖出"评级。(格隆汇) (资料图片) ...

远程医疗平台Hims & Hers Health最新季度销售额上升，该公司持续扩充治疗项目范围，订阅用户数量 也有所增长。 Dudum表示，GLP‑1类药物确实为业务增长提供了显著助力，但这类药物只是其全球化消费平台中单一 领域的单一疗法，而随着持续投入，该平台正变得更加强健、多元。 他称，Hims & Hers仅有一小部分订阅用户使用复方GLP‑1类药物，这表明平台的影响力远不止于减重 领域。 他补充道，尽管并非所有新业务都能达到减重业务的增长速度，但凭借超级碗广告后用户接受度的快速 提升，公司有信心睾酮治疗、更年期护理及检测服务业务在不久的将来年营收均突破1亿美元。 "这三大新业务板块不只是新增服务，更是我们与客户建立更深度联结、创造更多价值的起点。" 尽管这家远程医疗平台预计今年增长势头将延续，但其第一季度业绩指引低于华尔街预期。 截至当日收盘，其股价在过去一年累计下跌69.8%。 这份财报发布之际，Hims & Hers正面临诺和诺德提起的诉讼，后者要求禁止该公司销售其减重药物的 仿制品。诺和诺德指控Hims & Hers侵犯司美格鲁肽相关专利，而Hims & Hers则批评该诉讼是在打压平 价药物选 ...

JPMorgan maintains 2026 expense outlook; ROTCE target at 17% February 23, 20269:25 PM UTCUpdated ago By Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Business Hims & Hers forecasts 2026 revenue above estimates February 23, 2026 · 9:15 PM UTCHealthcare & Pharmaceuticalscategory · · ago JPMorgan Chase logo is seen in this illustration taken January 22, 2026. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab NE ...

Hims & Hers Health forecast 2026 revenue above estimates on Monday, betting on increased sales for its personalized healthcare offerings. ...

Market Overview - On February 19, U.S. stock markets opened lower and closed down, with all three major indices declining [1][2] - The Dow Jones Industrial Average fell by 0.54% to 49,395.16 points, the S&P 500 decreased by 0.28% to 6,861.89 points, and the Nasdaq Composite dropped by 0.31% to 22,682.73 points [2][3] Asset Management Sector - Blue Owl Capital announced the sale of $1.4 billion in loan assets from three private debt funds, raising concerns among investors about potential losses in the private loan sector [4] - Following this news, several asset management companies experienced significant stock declines: Blue Owl Capital down 5.93%, Blackstone down 5.37%, Apollo Global Management down 5.21%, Ares Management down 3.08%, and Brookfield down 2.68% [4] Software Industry - The software sector also showed weakness, with notable declines in stocks such as Cadence Design Systems down 2.76%, SAP down 2.41%, Intuit down 2.06%, and ServiceNow down 1.33% [4] - Concerns about artificial intelligence potentially disrupting the software industry were highlighted, with Mistral AI's CEO stating that over 50% of enterprise software could be replaced by this technology [4] Energy Sector - Energy stocks mostly rose amid ongoing tensions between the U.S. and Iran, with ConocoPhillips up 0.97% and Chevron up 0.49% [5] Retail Sector - Walmart's stock fell by 1.38% after the company provided a fiscal year profit guidance that fell short of market expectations, overshadowing its better-than-expected fourth-quarter results [5] Technology Stocks - Major tech stocks had mixed performances: Nvidia down 0.04%, Apple down 1.43%, Alphabet down 0.13%, Microsoft down 0.29%, Amazon up 0.03%, Meta up 0.24%, and Tesla up 0.12% [6][7] Chinese Stocks - The LiFeng Chinese stock index fell by 0.54%, and the Nasdaq Golden Dragon China Index decreased by 0.35% [8] - Popular Chinese stocks mostly declined, with Bawang Tea down 2.5%, Trip.com down 2.28%, Alibaba down 0.96%, and Pinduoduo down 0.94% [8] Company News - Amazon surpassed Walmart to become the highest-grossing company globally, reporting $717 billion in sales for the fiscal year ending December, compared to Walmart's $713.2 billion [9] - AMD announced it will support a $300 million loan to Crusoe, backed by chip products [10] - Hims & Hers Health is acquiring Australian digital health company Eucalyptus for up to $1.15 billion, which boosted its stock by approximately 7% in pre-market trading [11] - Yorkville America Equities LLC announced plans to acquire the Point Bridge America First ETF, focusing on investments aligned with former President Trump's "America First" ideology [12] - BE Semiconductor Industries reported fourth-quarter revenue of €166.4 million, exceeding analyst expectations, and projected a revenue growth of 5%-15% for the first quarter [13]

Group 1 - Hims & Hers Health's stock rose approximately 7% in pre-market trading [1] - The company announced the acquisition of Australian digital health service provider Eucalyptus [1] - The total transaction value could reach up to $1.15 billion [1]

Core Insights - Hims & Hers Health is facing challenges in finding new growth drivers after its original sexual-health franchises have matured, particularly following a controversial launch of weight-loss pills that faced backlash from Novo Nordisk and U.S. regulators [1][2] Company Strategy - Hims announced plans to offer a compounded oral semaglutide pill for $49, which is a version of Novo Nordisk's Wegovy, but retreated after warnings from U.S. FDA officials about the legality of such offerings [2] - The company has been positioning itself as an affordable healthcare provider, even investing in high-profile advertising campaigns [5] Financial Performance - Hims had less than $900 million in sales in 2023 but is projected to exceed $2.3 billion in sales by 2025, with expectations of $620 million in fourth-quarter sales, reflecting a 28% increase [6] - The company's sales growth rate has been robust, ranging from 59% to 94% over the past four years, but is forecasted to decline to around 17% over the next two years [7] Market Context - The obesity drug market is projected to reach annual sales of approximately $100 billion by 2030, with a significant portion expected to come from oral medications [8]

Core Insights - Hims & Hers Health is exploring new growth avenues as its initial sexual-health product lines reach maturity [1] - The company faced backlash from Novo Nordisk and U.S. regulators following the controversial launch of weight-loss pills [1] Company Overview - Hims & Hers Health is an online telehealth company that has primarily focused on sexual health products [1] - The company is now seeking to diversify its offerings to sustain growth as its original franchises mature [1] Industry Context - The launch of weight-loss pills by Hims & Hers Health has been met with significant criticism, indicating potential regulatory challenges in the telehealth and pharmaceutical sectors [1] - The response from established players like Novo Nordisk highlights the competitive landscape and the scrutiny new entrants may face in the health and wellness market [1]

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts for major pharmaceutical companies, integrated financial statements, discounted cash flow analysis, and market-specific analyses [1]

Group 1 - Deutsche Bank has lowered the target price for Hims & Hers Health from $42 to $31 while maintaining a "Hold" rating [1]